Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : TAR001
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : iOncologi
Deal Size : Undisclosed
Deal Type : Acquisition
iOncologi Acquires TargImmune Therapeutics
Details : Through the acquisition, iOncologi will strengthen it's oncology pipeline including TAR001, which is being evaluated preclinical stage for treating neoplasms.
Product Name : TAR001
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
March 14, 2025
Lead Product(s) : TAR001
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : iOncologi
Deal Size : Undisclosed
Deal Type : Acquisition